[Health prospects in the alternative strategies of renal replacement  therapies].
The authors are publishing the health outcome results of a cost-effectiveness analysis on renal replacement therapies. They analysed the mortality data of the main renal replacement therapies between the 3-year time period of 1994-1997 in a retrospective way. They found that although there is a high initial postoperative mortality risk of the surgical procedure, the kidney transplantation reduces the relative risk of 3-year mortality by 27.7% (p = 0.0601) in comparison with the waiting listed hemodialysis. This means 5.6% absolute risk reduction. As it is proved that transplantation improves quality of life of patients on renal replacement therapy, the loss of a potential donor decreases the expected quality adjusted life years (QALY) benefit of those dialysed patients who are on the waiting list.
Kaló
Z
Z
Novartis Hungária Kft., Budapest.
Járay
J
J
Nagy
J
J
Megyesi
A
A
Hídvégi
M
M
D000328:Adult; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D016030:Kidney Transplantation / Q000191:economics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000191:economics / Q000401:mortality; D017582:Renal Replacement Therapy / Q000191:economics* / Q000401:mortality*; D012306:Risk; D016896:Treatment Outcome